pSivida

pSivida plans to consolidate all R&D in current U.S. facility

Wednesday, July 27, 2016

pSivida, a leader in the development of sustained release drug delivery products primarily for eye diseases, is implementing a site consolidation plan in support of its product development program and plans to conduct all future research and product development in a single location. Subject to an employee consultation process required by local U.K. law, pSivida proposes to close its research facility in Malvern, U.K. and locate all research and product development activities in the company’s state-of-the-art, cGMP facility in Watertown, Massachusetts.

[Read More]